Cyclosporine for the Treatment of HTLV-1-Induced HAM/TSP: An Experience from a Case Report

HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) remains a challenging disease. Treatment options are scarce, and their safety and efficacy are currently a matter of concern. We present a case report describing our experience using cyclosporine in a patient with early HAM/TSP who...

Descripción completa

Detalles Bibliográficos
Autores principales: Sánchez-Montalvá, Adrián, Salvador, Fernando, Caballero, Estrella, Molina, Israel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2015
Materias:
4900
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4602838/
https://www.ncbi.nlm.nih.gov/pubmed/25569667
http://dx.doi.org/10.1097/MD.0000000000000382
Descripción
Sumario:HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) remains a challenging disease. Treatment options are scarce, and their safety and efficacy are currently a matter of concern. We present a case report describing our experience using cyclosporine in a patient with early HAM/TSP who started with a gait disturbance at Vall d’Hebron University Hospital (Barcelona) from August 2012 to October 2013. After 62 weeks of treatment, clinical improvement was observed and proviral load diminished. No safety concerns were observed. Cyclosporine seems to be effective in new-onset HAM/TSP or in chronic HAM/TSP that develops a relapse. However, the duration and safety profile of this steroid-sparing therapy remain unknown and should be further investigated.

Ejemplares similares